AQR Capital Management LLC Sells 284,831 Shares of Solventum Corporation $SOLV

Key Points

• AQR Capital Management LLC has reduced its stake in Solventum Corporation by 20%, selling 284,831 shares during the 1st quarter, now owning 1,142,129 shares valued at approximately $85.66 million.
• Solventum reported earnings per share of $1.69 for the most recent quarter, exceeding analysts' expectations of $1.45, along with a revenue of $2.16 billion.
• Equities analysts have a mixed outlook on Solventum, with four analysts rating it a "Buy" and one a "Sell", while the average target price stands at $85.75.

AQR Capital Management LLC lowered its position in Solventum Corporation (NYSE:SOLV - Free Report) by 20.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,142,129 shares of the company's stock after selling 284,831 shares during the quarter. AQR Capital Management LLC owned about 0.66% of Solventum worth $85,660,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in SOLV. Ameriprise Financial Inc. increased its holdings in shares of Solventum by 14.8% in the 4th quarter. Ameriprise Financial Inc. now owns 75,874 shares of the company's stock worth $5,023,000 after buying an additional 9,776 shares during the last quarter. BNP Paribas Financial Markets increased its holdings in shares of Solventum by 39.2% in the 4th quarter. BNP Paribas Financial Markets now owns 244,699 shares of the company's stock worth $16,165,000 after buying an additional 68,916 shares during the last quarter. Bank of America Corp DE increased its holdings in shares of Solventum by 5.1% in the 4th quarter. Bank of America Corp DE now owns 855,690 shares of the company's stock worth $56,527,000 after buying an additional 41,578 shares during the last quarter. Captrust Financial Advisors increased its holdings in shares of Solventum by 43.2% in the 4th quarter. Captrust Financial Advisors now owns 35,165 shares of the company's stock worth $2,323,000 after buying an additional 10,611 shares during the last quarter. Finally, Colonial Trust Co SC increased its holdings in shares of Solventum by 240.7% in the 4th quarter. Colonial Trust Co SC now owns 511 shares of the company's stock worth $34,000 after buying an additional 361 shares during the last quarter.

Solventum Trading Down 2.2%

SOLV traded down $1.66 during trading on Tuesday, hitting $72.94. 930,094 shares of the stock traded hands, compared to its average volume of 1,076,658. The firm has a market capitalization of $12.65 billion, a P/E ratio of 33.77, a price-to-earnings-growth ratio of 2.97 and a beta of 0.53. The company has a debt-to-equity ratio of 2.14, a current ratio of 1.22 and a quick ratio of 0.86. The firm has a 50-day moving average of $73.50 and a 200 day moving average of $72.76. Solventum Corporation has a 12-month low of $60.70 and a 12-month high of $85.92.

Solventum (NYSE:SOLV - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $1.69 earnings per share for the quarter, beating the consensus estimate of $1.45 by $0.24. The business had revenue of $2.16 billion during the quarter, compared to analysts' expectations of $2.12 billion. Solventum had a net margin of 4.52% and a return on equity of 29.93%. The firm's revenue for the quarter was up 3.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.56 EPS. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. Equities research analysts anticipate that Solventum Corporation will post 6.58 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have recently commented on SOLV. Morgan Stanley raised shares of Solventum from an "equal weight" rating to an "overweight" rating and increased their price target for the stock from $80.00 to $103.00 in a report on Tuesday, July 15th. Wells Fargo & Company upped their price objective on shares of Solventum from $75.00 to $79.00 and gave the company an "equal weight" rating in a research note on Friday, August 8th. KeyCorp initiated coverage on shares of Solventum in a research note on Friday, June 6th. They issued a "sector weight" rating for the company. Piper Sandler reaffirmed an "overweight" rating and issued a $94.00 price objective (up previously from $87.00) on shares of Solventum in a research note on Friday, August 8th. Finally, Wall Street Zen cut shares of Solventum from a "strong-buy" rating to a "buy" rating in a research note on Tuesday. Four equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $85.75.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.